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with diverse scientific and clinical backgrounds. In this process, the number of scale grades of the
originally proposed PVFS scale was reduced and descriptions of the grades were improved. After these
changes, a consensus was reached on the number/definitions of the grades, and method/timing of the scale
assessment. The relevance and potential impact of the scale was confirmed in three focus groups totaling
18 VTE patients, who suggested additional changes to the manual, but not to the scale itself. Using the
improved manual, the ฀-statistics between PVFS scale self-reporting and its assessment via the structured
interview was 0.75 (95%CI 0.58-1.0), and 1.0 (95%CI 0.83-1.0) between independent raters of the recorded
interview of 16 focus groups members. CONCLUSION We improved the PVFS scale and demonstrated
broad consensus on its relevance, optimal grades, and methods of assessing among international VTE
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A B S T R A C T
Introduction: We recently proposed a scale for assessment of patient-relevant functional limitations following an
episode of venous thromboembolism (VTE). Further development of this post-VTE functional status (PVFS) scale
is still needed.
Methods: Guided by the input of VTE experts and patients, we refined the PVFS scale and its accompanying
manual, and attempted to acquire broad consensus on its use.
Results: A Delphi analysis was performed involving 53 international VTE experts with diverse scientific and
clinical backgrounds. In this process, the number of scale grades of the originally proposed PVFS scale was
reduced and descriptions of the grades were improved. After these changes, a consensus was reached on the
number/definitions of the grades, and method/timing of the scale assessment. The relevance and potential
impact of the scale was confirmed in three focus groups totaling 18 VTE patients, who suggested additional
changes to the manual, but not to the scale itself. Using the improved manual, the κ-statistics between PVFS scale
self-reporting and its assessment via the structured interview was 0.75 (95%CI 0.58–1.0), and 1.0 (95%CI
0.83–1.0) between independent raters of the recorded interview of 16 focus groups members.
Conclusion: We improved the PVFS scale and demonstrated broad consensus on its relevance, optimal grades,
and methods of assessing among international VTE experts and patients. The interobserver agreement of scale
grade assignment was shown to be good-to-excellent. The PVFS scale may become an important outcome
measure of functional impairment for quality of patient care and in future VTE trials.
1. Introduction
Along with recurrent venous thromboembolism (VTE), bleeding and
mortality, both quality of life and functional limitations are important
outcome measures that matter greatly to VTE patients [1–7]. These two
issues are mostly determined by the presence and severity of leg or
chest pain, dyspnea, anxiety, post thrombotic panic syndrome, and
depression, all of which are important determinants of recovery after
VTE [4–6,8–21]. Persistent functional limitations and/or decreased
quality of life after an episode of VTE are framed within the concepts of
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the post-thrombotic syndrome (PTS) and post-pulmonary embolism
(PE) syndrome [2,22]. PTS manifests as chronic venous insufficiency in
a limb affected by deep vein thrombosis (DVT) caused by venous ob-
struction and/or venous reflux [22,23]. The post-PE syndrome includes
chronic thromboembolic pulmonary hypertension (CTEPH), chronic
thromboembolic pulmonary vascular disease (CTED), and persistent
right ventricular dysfunction, but also otherwise unexplained new or
progressive exercise intolerance after PE [2,24–26].
While there are validated questionnaires for the assessment of pain,
dyspnea, anxiety and depression, these were mostly not designed to rank
patients into meaningful categories and do not target functional outcomes
per se. The same holds true for measures of quality of life
[5,14,23,24,27,28]. Therefore, quality of life outcomes between treatment
strategies are difficult to put into a comprehensible perspective and may not
always serve their purpose when used as a main outcome measure in the
setting of an experimental study. Given these gaps, we recently proposed the
first version of the post-VTE functional status (PVFS) scale, which is meant
to be used as a comprehensive measure to quantify the consequences of VTE
on functional status. It covers the full spectrum of functional outcomes,
ranging from no symptoms to death, and focuses on both limitations in
usual duties/activities and changes in lifestyle (Appendix A) [11]. The scale,
required further development (Table 1).
In the current study, we sought to refine the scale and acquire broad
consensus on the methods of assigning a PVFS scale grade at a certain
time point, guided by the expertise of VTE specialists as well as by
patient focus groups. Moreover, we aimed to establish the reproduci-
bility of PVFS scale assessment.
2. Methods
2.1. Study design
The Delphi method was used to assess expert consensus among a panel
of VTE specialists with scientific and clinical expertise in measuring and
managing long-term outcomes of VTE across different patient subgroups. A
Delphi analysis is a widely used structured process to achieve consensus
through opinions and feedback from a group of informed experts [29–31].
The process is anonymous and focuses on a predefined dilemma, usually
lacking empirical evidence. The expert panel is consulted via questionnaires.
Responses are analyzed and used to guide the next round of new questions.
In the subsequent rounds of questions, experts are provided with the overall
results of the previous round of the Delphi study. The optimal level of
consensus is usually achieved after two or more rounds [32].
A patient focus group represents a qualitative research method in
which a small group of participants discuss a topic chaired by a mod-
erator [33]. It is an appropriate and suitable method to involve patients
in the development of scales and other medical instruments for various
medical conditions. Following a number of semi-structured questions to
help focus the group's discussion, participants can explore issues of
concern, propose changes and identify strategies for further exploration
of the topic at hand.
In both stages of the study, we aimed to achieve consensus and
explore the experts' and patients' view on six issues: 1) the relevance of
measuring functional limitations after VTE both in clinical trials and in
clinical practice, 2) whether current available tools are sufficiently re-
liable to assess functional limitations after VTE, 3) the appropriateness
of the PVFS scale for measuring functional limitations after VTE, 4)
whether the PVFS scale has sensible and representative scale categories,
5) whether the PVFS scale captures both PTS and post-PE syndrome,
and 6) how and when the scale should be measured.
2.2. Selection of experts and patients
Experts were selected based on the following criteria: 1) leaders in the
VTE field, as demonstrated by a strong publication track record and leading
roles in scientific societies; or 2) clinical experience in treating patients with
post-VTE complications. The panel of physicians and epidemiologists was
selected to represent a wide geographic area, to include both sexes, and to
cover broad medical specialties, including (pediatric) hematology, cardi-
ology, pulmonology, vascular medicine and vascular surgery. The experts
completed the questionnaires anonymously and were unaware of the
identity of the other experts involved. Patients were invited to participate in
the focus groups via mailings from the Netherlands Thrombosis Foundation
(patient association). As with the panel, we aimed to include patients who
do or did experience functional limitations after their VTE diagnosis, rather
than to represent the whole of VTE patients. Therefore, we did not apply
any selection criteria except for consenting to participation, accepting that
selection bias would occur.
2.3. Delphi and focus group processes
A multinational steering committee of four members was estab-
lished to oversee the process (DB, SB, BS and FK). A first version of the
Delphi questionnaire was drafted by two members (DB and FK). All
members of the steering committee provided feedback on the ques-
tionnaire and approved its final version. The first round of our Delphi
study consisted of a total of 10 multiple choice questions/statements
(Appendix B). Each question included a free text box for further ela-
boration. Additionally, a final open question was included, which al-
lowed the experts to provide any input about the PVFS scale, including
its design, and how it may be used. Subsequent rounds were planned
until consensus was reached, which had been predefined as a minimum
level of agreement of 70%, in line with previous Delphi reports
[34–37]. The Delphi questionnaire was distributed by using an online
Table 1
Proposed steps of development of performance outcome instruments, and current status of development of the post-VTE functional status scale.
Steps of development Status of the PVFS scale
1 Review of evidence for functional scales and tools assessing functional status in patients with VTE (first publication) ✓
2 Identification of the key characteristics of the modified Rankin Scale for patients with stroke in order to draft measure and item specifications, and
fields of applicability which may be relevant for patients with venous thromboembolism (first publication)
✓
3 Assemble a dedicated multidisciplinary work group (including patients, and physicians, nurses, and representatives of major societies) to achieve
consensus on the instrument (current manuscript)
✓
4 Formal rounds of review of the proposed categories of the ordinal scale from the dedicated multidisciplinary work group (current manuscript) ✓
5 Formal assessment of reliability and validity of the scale (current manuscript) ✓
6 Next research topics:
- Formal assessment of reliability and feasibility (e.g. logistics and costs) of the scale in clinical trials
- Formal evaluations of assessment methods; blinded versus non-blinded raters, and structured interview versus self-report
- Assessment of interrater agreement of structured interviews after translation into other languages
- Assessment of variability in time of the PVFS scale grades following the intended time points for assessing functional status
- Relating quality of life and utilities to functional status, with focus on cultural differences
Ongoing
7 Dissemination and implementation in both research protocols and clinical practice for routinely collected data analyses (quality indicator) Ongoing
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survey tool (Google Forms). Responses were filed at the experts' dis-
cretion until a given deadline date, a total of two reminders were sent
before reaching this date.
For the focus groups, semistructured interview questions were de-
veloped by the steering committee. The questions were divided into
three parts, namely engagement questions, exploration questions, and
exit questions (Table 2). The two-hour meetings were conducted in
Dutch and chaired by two members of the steering committee. All
participants agreed to a voice-recording of the meeting. Extraction of all
relevant suggestions and remarks that needed to be implemented in the
PVFS scale or its manual was done by the steering committee.
2.4. Interrater agreement
Interobserver variability was determined by comparing the self-re-
ported PVFS scale grade to the scale grade identified via the structured
interview. One member of the steering committee interviewed the pa-
tients from the focus groups in a standardized way according to the
updated manual for the structured interview (Appendix C). These in-
terviews were recorded on tape. Before the interview was conducted,
patients were given the self-report flowchart and corresponding table
and were given instructions on how to determine their PVFS scale grade
(Appendix C). Upon completion of the interview, the interviewer noted
the identified PVFS scale grade, independently and blinded to the
scoring determined by the patient. Two additional raters -in-
dependently from the interviewer and patient and blinded to both of
their ratings- reevaluated the recording and assigned the patients to a
scale grade in accordance with the manual for the structured interview.
2.5. Analysis
Descriptive statistics and interobserver variability were calculated using
SPSS version 25.0.0 (SPSS, IBM). The interobserver agreement of PVFS scale
assessment between the patients and the raters as well as between the raters
themselves was assessed by calculating the κ-statistic. The k-statistic was
interpreted as follows: poor (<0.20), fair (0.21–0.40), moderate
(0.41–0.60), good (0.61–0.80) or excellent (0.81–1.00) [38].
3. Results
3.1. Delphi analysis
In April 2019, the first round of the Delphi questionnaire was dis-
tributed among 70 international VTE experts. Of those, 53 (76%) con-
sented to participate and completed the questionnaire. The expert panel
included VTE specialists practicing in 15 different countries. A total of
48 out of 53 participants completed the full Delphi procedure. Among
them, 17 were women. Several specialties were represented, including
(pediatric) hematology (n = 21), vascular medicine/surgery (n = 13),
pneumology (n = 10), cardiology (n = 3), radiology (n = 1), psy-
chologists (n = 2) and clinical epidemiology (n = 3).
Following compilation of the first Delphi round, immediate con-
sensus was reached on 5 of 10 questions/statements. The vast majority
agreed that measuring functional outcomes after VTE was relevant for
both research purposes (98%) and clinical practice (96%). Also, the
panel considered current tools (among others Villalta Score, Venous
Clinical Severity Score, New York Heart Association Classification,
Modified Medical Research Council Dyspnea Scale, 6-minute walk
distance, pulmonary function test and quality of life measures) un-
satisfactory reliable for both research purposes (73%) and clinical
practice (83%). They agreed that the PVFS scale would to be a poten-
tially helpful tool for these purposes (79% and 71%, respectively).
Further, the experts considered the design of the PVFS scale to be op-
timal (84%) and its manual to be clear and complete (78%).
The Delphi panel, however, clearly indicated that the originally pro-
posed 7-level ordinal scale needed to be improved in regards to two main
points: 1) the score should better reflect functional impairment related to
PTS and 2) the categories needed to be more distinctive. Moreover, the
impact of anxiety and depression needed to be addressed more explicitly.
All comments were discussed within the steering committee, which led to
modifications to the scale and manual. Specifically, the following adjust-
ments were made (in addition to linguistic tweaking): 1) the scale was
adjusted to be more sensitive to DVT-associated functional limitations by
replacing ‘symptoms/discomfort’ to ‘symptoms, pain, or anxiety’ in the
grade description (in this way, psychological aspects of physical functioning
were incorporated as well); 2) specific symptoms/signs (such as dyspnea at
rest or venous ulceration) were removed to avoid measuring symptoms
rather than their functional impact; 3) one scale grade was removed
(“moderately-severe functional limitations”) to facilitate distinctive grades
in the middle spectrum of severity, and 4) ‘death’ was considered as a ‘D’
class instead of ‘grade 6’ to make it more visually distinctive.
The updated scale and manual were sent out for a second Delphi
questionnaire round; the same respondents were able to see which of
the multiple-choice options of the first round achieved the highest level
of consensus, and how and why adjustments had been made. The
second questionnaire consisted of four statements, all of which
achieved consensus (Fig. 1): 89% of 48 respondents agreed that the
adjusted scale had additional value to quality of life questionnaires and
exercise tests to measure functional outcome after VTE; 94% agreed
that the adjusted scale reflected functional limitations after both DVT
and PE; 92% agreed that the adjusted scale comprised sensible, clear
and distinctive scale grades, and 83% agreed that the scale could best
be assessed at the time of VTE diagnosis and after 90 days, leaving
explicit room for longer follow-up depending on the clinical setting or
objective of a clinical trial. The respondents advised to mention the
possibility of measuring the pre-VTE functional status, which was then
incorporated as an optional item in order to obtain a true picture of
change in functional status after the VTE event.
Table 2
Semi-structured interview questions for the patients focus groups.
Engagement questions Explorative questions Exit question
Can you tell about yourself and your experience
with VTE?
Do you consider assessment of functional limitations after VTE to be
relevant? Was this assessed in your case, and how?
Is there anything else that you would like to
say about the PVFS scale?
How did the VTE influence your physical and
mental condition?
What do you think of the PVFS scale and how can it be used?
How did the VTE influence your working, family,
and social life?
Are the scale categories straightforward and rational? Are any important
aspects of functional outcomes after VTE missing?
Have you been/are you functionally impaired by
the VTE?
Is the wording of the scale categories adequate and comprehensible?
Is the interview (and corresponding manual) adequate?
Is the patient self-report flowchart (and corresponding manual) adequate?
How often is the PVFS scale to be assessed, and would you prefer self-report
over a structured interview?
Do you think it should be implemented in future clinical trials on optimal
treatment of VTE?
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3.2. Patient focus groups
A total of 18 patients responded to the invitation and participated in
one of three patient focus group sessions. Their ages ranged between 21
and 70 years, and two were men. Their background was diverse: the
group included physicians, nurses, teachers, journalists and house-
cleaners. Several patients had administrative jobs, and one was retired
at the time of the VTE diagnosis. Most had been diagnosed with both
DVT and acute PE (n = 9), and 11 had recurrent VTE. None of the
patients were known with CTEPH or severe PTS with leg ulcers. The
mean time since last VTE event varied from 6 to 108 months, with most
patients (67%) between 0 and 2 years after their event.
All participants highlighted their appreciation of focused attention to
functional limitations after VTE. All 18 considered it a relevant topic as they
had (and most of them still) suffered greatly from the long-term impact of
their VTE in regards to their professional and personal life. Several had lost
their jobs or had to reduce the intensity of their work. Furthermore, several
marriages and relations were broken, and most of them considered the VTE
a traumatic experience. The quote “I had a different life before than after the
VTE diagnosis” by one of the focus group participants was heartedly en-
dorsed by the other participants. Many still faced anxiety due to the pos-
sibility of recurrent events. In general, they recognized the lack of attention
from their treating physician to aspects of their recovery other than man-
agement of the anticoagulant treatment. The lack of a status scale such as
the PVFS scale was agreed on to be an unmet clinical need. The general
consensus was that the introduction of the PVFS scale could help address
persistent functional limitations in the (outpatient) clinic, but also to help
explain their functional status to their families and relatives. Also, the pa-
tients generally agreed that the scale reflected functional limitations after
both DVT and PE. Most patients could imagine self-reporting the scale via a
mobile application, at fixed time points during their follow-up care but also
on their own initiative to better capture good and/or bad weeks. This latter
option would give patients a sense of more control of their treatment.
At least half of patients reported that they had some reservations toward
the self-report flowchart and table. The main concern raised was with the
distinction between moderate and severe functional limitations (scale grade
2 and 3). Textual changes were suggested to make it clearer that grade 2
involves being able to do all ones' duties/activities, even at a slower pace or
extended over a longer period of time, and that grade 3 indicates the in-
ability to perform a particular duty/activity. The manual to the structured
interview was adjusted accordingly. Moreover, it was suggested not to ac-
tually provide a ‘grade name’ to the limitations themselves (e.g. moderate
limitations), because of its subjectiveness, but rather, to stick to describing
the limitations. The scale (after adjustments suggested and approved by the
Delphi panel) was considered to be adequate, and no further changes were
suggested or incorporated by the patients. The final scale is shown in
Table 3; the final patient self-report flowchart and corresponding table are
shown in Fig. 2 and Table 4.
3.3. Interrater agreement
Structured interviews were conducted and recorded for 16 focus group
participants. There was full agreement between the patient self-reported
scale grade and the grade assigned by the interviewer in 14/16 patients
(88%) for a kappa statistic of 0.75 (95%CI 0.58–1.0). The two discrepancies
were in patients who rated themselves a grade 2 while the interviewer
categorized them as grade 3. Two independent raters blinded to the grading
by the patient and the interviewer evaluated the recorded interview post-
hoc, were both in full agreement with each other and with the interviewer,
for a kappa statistic of 1.0 (95%CI 0.83–1.0).
4. Discussion
The concept of the PVFS scale was endorsed by a large panel of
international VTE experts as well as by VTE patients of diverse ages and
backgrounds. The results of our Delphi consensus indicate that the PVFS
90%
10%
1. In your opinion, could the adjusted 
interview-based scale have addi!onal value to 
quality of life ques!onnaires and exercise tests 




2. In your opinion, does the adjusted 
interview-based scale reflect on func!onal 
limita!ons a"er both pulmonary embolism 




3. In your opinion, does the 
adjusted interview-based scale 





4. We propose to measure func!onal limita!ons at least at the 
moment of hospital discharge and a"er 90 days of follow-up. 
In your opinion, do you agree that these are reasonable !me points 
for clinical trials in VTE?
Yes No
Fig. 1. Statements reaching consensus in the second round of the Delphi analysis.
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scale may help to address an unmet clinical need. Moreover, we were
able to improve the original proposed scale, refine the optimal assess-
ment method, and establish good-to-excellent interobserver agreement
between different medical professionals as well as between the struc-
tured interview and the patient self-report. The development of the
scale is in an advanced stage, and it can be now used in clinical practice
and implemented in clinical trials (Table 1).
In the field of stroke research, the modified Rankin Scale (mRS) - by
which the authors were inspired when proposing and developing the
PVFS scale - has achieved a key position as an important, and often
primary, outcome of seminal trials that have subsequently shaped the
current standard of care [39,40]. With the introduction of the PVFS
scale, VTE trials can now start to include an overall outcome measure
that captures the broad range of physical and psychological long-term
complications of VTE and its treatment, expressed in meaningful cate-
gories that are linked to quality of life with both social and economic
impact (e.g. healthcare costs and societal costs). This scale could be
used to identify patients with slower than expected recovery after VTE.
In such cases, the culprit symptom can be identified and targeted, al-
though this latter is beyond the scope of the scale itself. Another ex-
ample of how the score may be used is to establish the optimal duration
of treatment in unprovoked VTE, in which the balance between the
impact of relatively frequent recurrences of VTE and less frequent -but
more impactful- occurrences of bleeding complications is still a matter
of debate and research [41–44]. A third example where the PVFS scale
may help to determine conclusively the optimal treatment strategy is
the dilemma of the benefit of early pharmacomechanical catheter-di-
rected thrombolysis in iliofemoral DVT, which has been associated with
better quality of life in some studies, but not with less PTS [45,46].
Based on our results presented here, the PVFS scale has been included
as a secondary outcome in four clinical trials scheduled to start on short
notice: PEITHO-3 (PHRCN_16-0580), SAFE-SSPE (NCT04263038), L-
TRRiP (ZonMw 848017007) and ARIVA (NCT04128956). We will learn
more about the value of the PVFS scale by analysing the results of the
PVFS scale assessments within those and other clinical trials on corre-
lation between PVFS scale grades and health-related quality of life or
Table 3
Final post-VTE functional status scale as agreed upon by the Delphi panel and patient focus groups (full manual for structured interview and patient self-report
provided in Appendix C). Providing a reference value (pre-VTE grade) is optional and should refer to the functional status 1 month prior to the VTE diagnosis.
PVFS scale grade Description
0 No functional limitations All usual duties/activities at home or at work can be carried out at the same level of intensity. Symptoms, pain and anxiety are absent.
1 Negligible functional limitations All usual duties/activities at home or at work can be carried out at the same level of intensity, despite some symptoms, pain, or anxiety.
2 Slight functional limitations Some usual duties/activities at home or at work are carried out at a lower level of intensity or are occasionally avoided due to symptoms,
pain, or anxiety.
3 Moderate functional limitations Usual duties/activities at home or at work have been structurally modified (reduced) due to symptoms, pain, or anxiety.
4 Severe functional limitations Assistance needed in activities of daily living due to symptoms, pain, or anxiety: nursing care and attention are required.
D Death Death occurred before the scheduled assessment.
Grade 4
Do you need to avoid or reduce 
du!es/ac!vi!es or spread these over !me?




Do you suffer from
symptoms, pain, or anxiety?
No
Grade 3
What was your func!onal status before your VTE diagnosis?   [optional]
Are there duties/activities at home or at work which 
you are no longer able to perform yourself?
Can you live alone without any assistance from another person? 
(e.g. independently being able to eat, walk, use the toilet and manage routine daily hygiene)
Yes
Grade 4Grade 0 Grade 1 Grade 2 Grade 3
No Yes
Fig. 2. Flowchart for patient self-report of the post-VTE functional status scale (full manual for structured interview and patient self-report provided in Appendix C).
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more specific components of PTS and the post-PE syndrome (e.g. pain
or dyspnea). In the clinical setting, the PVFS scale may help health care
providers to monitor the recovery of individual patients, may better
identify complications such as CTEPH at an early stage and help ex-
plaining the impact of persistent symptoms to the treating physician
and relatives.
The main strength of this study is the broad consensus reached
among a large sample of international experts from various back-
grounds, as well as the clear endorsement of the PVFS scale by the
patient focus groups. The scale and its manual were refined to a point
with good-to-excellent interrater agreement, either self-reported or as-
sessed via a structured interview, underlining its validity when used as
an outcome of clinical trials. Although patient self-reporting is probably
the most practical approach for collecting PVFS scale outcome data, the
structured interview is the preferred mode of assessment from a sci-
entific point of view until the value of self-reported data has been es-
tablished by future research.
This study is limited by an obvious selection bias in the patient focus
groups: only patients with moderate to severe presentations of PTS and/
or post-PE syndrome responded to our call, leading to a probable
overestimation of the relevance for VTE patients as a whole group. Of
note, this bias is inherent to any outcome measure since generally the
majority of patients would never meet a given endpoint. Another po-
tential limitation lies in using focus groups to obtain qualitative data.
There is a risk of data bias if more forthright participants dominate the
discussions. This risk was ameliorated by using an experienced and
unprejudiced researcher to facilitate discussions and ensure all parti-
cipants were involved. Also, while we involved a broad international
panel of VTE experts and developed the first versions of the scale in the
English language, only Dutch patients participated in the focus groups
and the interobserver assessment was only tested in the Dutch lan-
guage. Hence, the scale and its manual for the structured interview and
patient self-report need to be evaluated in other countries and lan-
guages. Still, because of the simplicity of the PVFS scale, we do not
expect much different scale performance or interobserver agreement
when translated into other languages.
In conclusion, we demonstrated broad consensus on the relevance
and methods of assessment of the PVFS scale among international VTE
experts and patients. Based on their comments and suggestions, the
scale and its manual were improved after which the interobserver
agreement of scale assessment in our study was good-to-excellent.
These findings suggest that the PVFS scale can be integrated as a re-
levant outcome measure in future clinical trials as well as in daily
clinical practice to monitor patient recovery.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.thromres.2020.03.020.
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Table accompanying the flowchart for patient self-report of the post-VTE functional status scale (full manual for structured interview and patient self-report provided
in Appendix C).
How much are you currently affected in your everyday life by the VTE?
Please indicate which one of the following statements applies to you most. Please tick only one box at a time.
Corresponding PVFS scale grade if the box is
ticked
I have no limitations in my everyday life and no symptoms, pain, or anxiety related to the VTE. ⎕ 0
I have negligible limitations in my everyday life as I can perform all usual duties/activities, although I still have persistent
symptoms, pain, or anxiety.
⎕ 1
I suffer from limitations in my everyday life as I occasionally need to avoid or reduce usual duties/activities or need to spread
these over time due to symptoms, pain, or anxiety. I am, however, able to perform all activities without any assistance.
⎕ 2
I suffer from limitations in my everyday life as I am not able to perform all usual duties/activities due to symptoms, pain, or
anxiety. I am, however, able to take care of myself without any assistance.
⎕ 3
I suffer from severe limitations in my everyday life: I am not able to take care of myself and therefore I am dependent on
nursing care and/or assistance from another person due to symptoms, pain, or anxiety.
⎕ 4
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